Proprietary Platforms
GRAd Platform
A Next-Generation Adenoviral Vector for Powerful Immune Responses
The GRAd platform is ReiThera’s proprietary adenoviral vector derived from a rare gorilla adenovirus—engineered to combine low pre-existing immunity, strong immunogenicity, and scalable production.
Key Advantages
1
Low Human Seroprevalence
Enables potent priming and booster regimens across global populations
2
Robust Immunity
Induces durable T-cell and antibody responses in preclinical and clinical studies
3
Thermostable
Stable at +4°C to 37°C, removing cold-chain limitations
Proprietary Cell Lines
High-Performance Cell Systems for Scalable Vector Production
At the core of ReiThera’s manufacturing excellence are our proprietary cell lines—engineered for high-yield, GMP-compliant production of viral vectors. Designed to meet the demands of next-generation vaccines and gene therapies, these platforms deliver scalability, consistency, and regulatory confidence.
GRAd Platform Applications
Versatile for Vaccines and Immunotherapies
The GRAd platform—powered by ReiCell35s—has been successfully applied to:
- Infectious disease vaccines
- Oncology programs
- Personalized and multivalent vaccine strategies
Its adaptability, strong immune profile, and manufacturing flexibility make it ideal for both monovalent and multivalent regimens.
